Abstract
Traditionally, overall survival (os) has been considered the "gold standard" for evaluating new systemic oncologic therapies, because death is easy to define, is easily compared across disease sites, and is not subject to investigator bias. However, as the available options for continuing therapy increase, the use of os as a clinical trial endpoint has become problematic because of the increasing crossover and contamination of trials. As a result, the approval of promising new therapies may be delayed.Many clinicians believe that progression-free survival (pfs) is a more viable option for evaluating new therapies in metastatic and advanced renal cell carcinoma. As with all endpoints, pfs has inherent biases, and those biases must be addressed to ensure that trial results are not compromised and that they will be accepted by regulatory authorities. In this paper, we examine the issues surrounding the use of pfs as a clinical trial endpoint, and we suggest solutions to ensure that data integrity is maintained.
Highlights
Colorectal cancer is the third most common malignancy worldwide and the second cause of cancer death in both sexes in the developed world 1
Meaningful advances have been achieved with the introduction of new chemotherapeutic agents and the targeted monoclonal antibodies in various therapeutic schedules 7–9
Prolonged durations of therapy and the doselimiting neurotoxicity of oxaliplatin have prompted a shift from the conventional paradigm of treatment until progression or toxicity, to chemotherapy with planned interruptions
Summary
Colorectal cancer is the third most common malignancy worldwide and the second cause of cancer death in both sexes in the developed world 1. One quarter of patients with colorectal cancer have liver metastases at the time of diagnosis, and among those with initially localized disease, 25%–30% will present with metastases in the following 2–3 years 2,3. The life expectancy for patients with metastatic colorectal cancer (mcrc) ranges from 5 months to 9 months 2,4
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.